PROM1 and hepatocellular carcinoma: Their results showed that blocking Pyruvate Dehydrogenase Kinase 4 (PDK4) and Lactate dehydrogenase A (LDHA) significantly reduced CD133 + stemness features and helped patients overcome sorafenib resistance (chemotherapy medication currently used for hepatocellular cancer).